Why It Matters
Alvotech, an Icelandic pharmaceutical company, has hired a lobbying firm to navigate escalating tariff pressures on imported drugs. CGCN Group LLC registered the company as a new lobbying client in mid-August to focus on health, manufacturing, and tariff issues.
Broader Context
Section 232 tariffs on patented pharmaceuticals formally took effect on July 31. An April 2026 White House proclamation mandated that the Commerce Department review biosimilar and generic exemptions within one year, creating a potential policy cliff in 2027. Seeking Alpha analysts characterized Alvotech as a potential victim of pharma tariff threats. President Trump announced plans to impose 25% tariffs on imported pharmaceuticals in February 2025.
The Bottom Line
The Commerce Department prepares to recommend potential additions to existing tariff regimes.
CGCN Group LLC brought on Kelly Lange, a Partner at the firm with prior congressional experience, to lead Alvotech's lobbying efforts. Lange previously worked with Rep. John Shimkus (R-IL-15) and has lobbied on behalf of other health companies including CSL Seqirus and Bavarian Nordic Inc.
Spot something wrong? Report an issue with this article